No association of the NFKB1 insertion/deletion promoter polymorphism with survival in patients with gastric cancer

Jpn J Clin Oncol. 2009 Aug;39(8):497-501. doi: 10.1093/jjco/hyp056. Epub 2009 Jun 9.

Abstract

Objective: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NFKB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma.

Methods: Four hundred and seventy two consecutive patients with curatively resected gastric adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue and the -94 insertion/deletion ATTG polymorphism of NFKB1 determined using a polymerase chain reaction-restriction fragment length polymorphism assay.

Results: The NFKB1 promoter gene polymorphism was successfully amplified in 97.8% of the cases. There were no sexual differences in relation to the genotype and allele. No correlation was observed between the frequency of the genotype or allele and the T, N or M stage. The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer.

Conclusions: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma.

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / mortality
  • Adenocarcinoma / secondary
  • Adult
  • Aged
  • Aged, 80 and over
  • DNA, Neoplasm / genetics
  • DNA, Neoplasm / metabolism
  • Feasibility Studies
  • Female
  • Gene Deletion
  • Humans
  • Korea
  • Male
  • Middle Aged
  • Mutagenesis, Insertional
  • NF-kappa B p50 Subunit / genetics*
  • Neoplasm Staging
  • Polymerase Chain Reaction
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • Promoter Regions, Genetic / genetics*
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / mortality*
  • Stomach Neoplasms / pathology
  • Survival Rate
  • Treatment Outcome

Substances

  • DNA, Neoplasm
  • NF-kappa B p50 Subunit
  • NFKB1 protein, human